Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells
FEBS Letters · 2025-12 · 599 (23) · 3524-3536
DOI: 10.1002/1873-3468.70166 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Letters, online erschienen am 15.09.2025. Verfasst von Seiji Nomura und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Kurume University School of Medicine, Japan. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Adenosine Triphosphate, Liver Cirrhosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The protective effects of imeglimin, a recently approved antidiabetic agent, against liver fibrosis have not been previously evaluated. In this study, we demonstrated that 8‐week administration of imeglimin attenuated immune cell infiltration and reduced collagen deposition, improving fibrosis stage in a thioacetamide‐induced murine model. Further analyses focusing on hepatic stellate cells (HSCs), the primary effector cells in fibrogenesis, revealed decreased expression of α‐smooth muscle actin and desmin, markers of HSC activation. Mechanistically, a clinically relevant low concentration (10 μ m ) of imeglimin reduced intracellular vesicular ATP accumulation and subsequently suppressed ATP release from HSCs in vitro . These findings suggest that imeglimin may exert anti‐inflammatory and antifibrotic effects by inhibiting vesicular ATP release and ATP‐mediated purinergic signaling. Impact statement At clinically relevant doses, imeglimin inhibits vesicular ATP release from hepatic stellate cells, reducing inflammatory infiltration and fibrotic collagen accumulation. These findings support its evaluation as a combined metabolic and antifibrotic therapy for MASLD and other chronic liver conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry, Kurume University School of Medicine, Japan.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan.
ORCID-Profile: Seiji Nomura
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Nomura, S., Wang, L., Hasuzawa, N., Nagayama, A., Moriyama, S., Ashida, K., Moriyama, Y., Nomura, M., & Yamamoto, K. (2025). Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells. FEBS Letters, 599(23), 3524-3536. https://doi.org/10.1002/1873-3468.70166
Vancouver
Nomura S, Wang L, Hasuzawa N, Nagayama A, Moriyama S, Ashida K, et al. Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells. FEBS Letters. 2025;599(23):3524-3536. doi:10.1002/1873-3468.70166
BibTeX
@article{Nomura2025,
author = {Nomura, Seiji and Wang, Lixiang and Hasuzawa, Nao and Nagayama, Ayako and Moriyama, Sawako and Ashida, Kenji and Moriyama, Yoshinori and Nomura, Masatoshi and Yamamoto, Ken},
title = {Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells},
journal = {FEBS Letters},
year = {2025},
volume = {599},
number = {23},
pages = {3524--3536},
doi = {10.1002/1873-3468.70166}
}
EUVIMED